Dec 30, 2021 · Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD ...

Jan 25, 2024 · In this issue of Blood, Othman et al use retrospective data to show the utility of measurable residual disease (MRD) monitoring of patients with NPM1 acute myeloid leukemia (AML) in de novo treatment using venetoclax-based regimens. 1. MRD assessments have the potential to improve outcomes for patients with AML.

Mar 22, 2018 · Minimal or, more appropriately, measurable residual disease (MRD) denotes the presence of leukemia cells down to levels of 1:10 4 to 1:10 6 white blood cells (WBCs), compared with 1:20 in morphology-based assessments.

Jun 13, 2023 · Measurable residual disease (MRD) is a critical diagnostic tool that predicts disease progression and is increasingly used as an important end point to monitor disease status and evaluate novel treatments for leukemia.

Measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) has an established role in disease prognostication, particularly in guiding decisions for hematopoietic cell transplantation in first remission.

Dec 30, 2021 · Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments.

Mar 22, 2018 · Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis.

The MRD in AML project will investigate the use of genetic tests to improve the accuracy of MRD detection approaches, help establish MRD as a validated biomarker in AML, and generate important molecular information about this disease.

Jan 21, 2022 · In recent years, the prognostic value of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) has been established, and early evidence suggests that MRD analysis may help to guide and personalize treatment decisions.

In the context of precision medicine, assessment of minimal residual disease (MRD) has been used in acute myeloid leukemia (AML) to direct individual treatment programs, including allogeneic stem cell transplantation in patients at high-risk of relapse.